150 related articles for article (PubMed ID: 36990047)
21. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
22. Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance
Starrett JH; Guernet AA; Cuomo ME; Poels KE; van Alderwerelt van Rosenburgh IK; Nagelberg A; Farnsworth D; Price KS; Khan H; Ashtekar KD; Gaefele M; Ayeni D; Stewart TF; Kuhlmann A; Kaech SM; Unni AM; Homer R; Lockwood WW; Michor F; Goldberg SB; Lemmon MA; Smith PD; Cross DAE; Politi K
Cancer Res; 2020 May; 80(10):2017-2030. PubMed ID: 32193290
[TBL] [Abstract][Full Text] [Related]
23. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
[TBL] [Abstract][Full Text] [Related]
24. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.
Yao Z; Fenoglio S; Gao DC; Camiolo M; Stiles B; Lindsted T; Schlederer M; Johns C; Altorki N; Mittal V; Kenner L; Sordella R
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15535-40. PubMed ID: 20713723
[TBL] [Abstract][Full Text] [Related]
25. Characterising acquired resistance to erlotinib in non-small cell lung cancer patients.
Karachaliou N; Codony-Servat J; Bracht JWP; Ito M; Filipska M; Pedraz C; Chaib I; Bertran-Alamillo J; Cardona AF; Molina MA; Rosell R
Expert Rev Respir Med; 2019 Oct; 13(10):1019-1028. PubMed ID: 31411906
[No Abstract] [Full Text] [Related]
26. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.
Awasthi S; Maity T; Oyler BL; Qi Y; Zhang X; Goodlett DR; Guha U
J Proteomics; 2018 Oct; 189():48-59. PubMed ID: 29660496
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
28. Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation.
Zheng LP; Chen LY; Liao XY; Xu ZH; Chen ZT; Sun JG
BMC Cancer; 2018 Nov; 18(1):1070. PubMed ID: 30400855
[TBL] [Abstract][Full Text] [Related]
29. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Zhang H; Han B; Lu H; Zhao Y; Chen X; Meng Q; Cao M; Cai L; Hu J
Cancer Lett; 2018 Oct; 433():186-198. PubMed ID: 29981430
[TBL] [Abstract][Full Text] [Related]
30. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
[TBL] [Abstract][Full Text] [Related]
31. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
[TBL] [Abstract][Full Text] [Related]
32. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
Markóczy Z; Sárosi V; Kudaba I; Gálffy G; Turay ÜY; Demirkazik A; Purkalne G; Somfay A; Pápai-Székely Z; Rásó E; Ostoros G
BMC Cancer; 2018 May; 18(1):598. PubMed ID: 29801465
[TBL] [Abstract][Full Text] [Related]
33. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.
Bousquet Mur E; Bernardo S; Papon L; Mancini M; Fabbrizio E; Goussard M; Ferrer I; Giry A; Quantin X; Pujol JL; Calvayrac O; Moll HP; Glasson Y; Pirot N; Turtoi A; Cañamero M; Wong KK; Yarden Y; Casanova E; Soria JC; Colinge J; Siebel CW; Mazieres J; Favre G; Paz-Ares L; Maraver A
J Clin Invest; 2020 Feb; 130(2):612-624. PubMed ID: 31671073
[TBL] [Abstract][Full Text] [Related]
34. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
35. Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Wu K; Guo C; Li R
Medicine (Baltimore); 2019 May; 98(18):e15489. PubMed ID: 31045832
[TBL] [Abstract][Full Text] [Related]
36. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
[TBL] [Abstract][Full Text] [Related]
37. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
[TBL] [Abstract][Full Text] [Related]
38. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
[TBL] [Abstract][Full Text] [Related]
39. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Amato KR; Wang S; Tan L; Hastings AK; Song W; Lovly CM; Meador CB; Ye F; Lu P; Balko JM; Colvin DC; Cates JM; Pao W; Gray NS; Chen J
Cancer Res; 2016 Jan; 76(2):305-18. PubMed ID: 26744526
[TBL] [Abstract][Full Text] [Related]
40. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
Lin Y; Higashisaka K; Shintani T; Maki A; Hanamuro S; Haga Y; Maeda S; Tsujino H; Nagano K; Fujio Y; Tsutsumi Y
Sci Rep; 2020 Mar; 10(1):4748. PubMed ID: 32179851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
